Generic Name and Formulations:
Ecallantide 10mg/mL; soln for SC inj; preservative-free.
Shire US, Inc.
Indications for KALBITOR:
Treatment of acute attacks of hereditary angioedema (HAE).
Give 30mg SC in three 10mg (1mL) inj into abdomen, thigh, or upper arm. May give additional 30mg within 24hrs if attack persists.
<12yrs: not established.
Have medical support available to manage anaphylaxis and hereditary angioedema. Monitor closely for hypersensitivity reactions. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.
Plasma kallikrein inhibitor.
Headache, nausea, diarrhea, pyrexia, inj site reactions, nasopharyngitis, fatigue, upper respiratory tract infection, pruritus, upper abdominal pain; anaphylaxis, antibody formation.
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Undifferentiated Headaches Common in Children, Adolescents
- Smoking Associated With Increased Relapse Rate in Interferon Beta-Treated Relapsing-Remitting MS
- Frontotemporal Dementia, Frontotemporal Lobar Degeneration Symptoms More Common Later in Life
- No Reduction in Cerebral Perfusion With Intensive Blood Pressure Lowering
- Successful Delirium Prevention in Critically Ill With Dexmedetomidine